Inhibition of mTOR by rapamycin enhances killing of CML cells by imatinib mesylate and overcomes certain forms of imatinib resistance.

被引：0
|
作者：
Halbur, L [1 ]
Ly, C [1 ]
Ong, ST [1 ]
机构：
[1] Univ Calif Irvine, Dept Med, Dept Hematol Oncol, Irvine, CA USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
242
引用
收藏
页码：72A / 72A
页数：1
相关论文
共 35 条
  • [1] Regulation of pathways downstream of mTOR by imatinib mesylate in CML cells.
    Aranha, O.
    Kaur, S.
    Smith, J.
    Sassano, A.
    Platanias, L. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 359S - 359S
  • [2] Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance
    Zhang, Min
    Fu, Wuxia
    Prabhu, Sharmila
    Moore, James C.
    Ko, Je
    Kim, Jung Woo
    Druker, Brian J.
    Trapp, Valerie
    Fruehauf, John
    Gram, Hermann
    Fan, Hung Y.
    Ong, S. Tiong
    MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (20) : 6496 - 6509
  • [3] Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition
    Niu, Chang-Chun
    Zhao, Chen
    Zhang, Xiao-Li
    Pan, Jing
    Zhao, Chen
    Wu, Wei-Ru
    Li, Zhi-Qiang
    Liu, Tao
    Yang, Zhong
    Si, Wei-Ke
    LEUKEMIA RESEARCH, 2013, 37 (11) : 1532 - 1537
  • [4] Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
    H G Jørgensen
    E K Allan
    S M Graham
    J L Godden
    L Richmond
    M A Elliott
    J C Mountford
    C J Eaves
    T L Holyoake
    Leukemia, 2005, 19 : 1184 - 1191
  • [5] Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
    Jorgensen, HG
    Allan, EK
    Graham, SM
    Godden, JL
    Richmond, L
    Elliott, MA
    Mountford, JC
    Eaves, CJ
    Holyoake, TL
    LEUKEMIA, 2005, 19 (07) : 1184 - 1191
  • [6] Treatment outcomes for imatinib mesylate and allogeneic stem cell transplantation in patients with CML based on RQ-PCR, and the efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
    Sohn, Sang Kyun
    Cho, Yoon Young
    Ahn, Byung Min
    Chae, Yee Soo
    Kim, Jong Gwang
    Moon, Joon Ho
    BLOOD, 2006, 108 (11) : 273B - 273B
  • [7] Silencing Lyn kinase overcomes resistance to imatinib in Bcr-Abl-dependent CML cells
    Wu, Ji Yuan
    Talpaz, Moshe
    Donato, Nicholas J.
    CANCER RESEARCH, 2006, 66 (08)
  • [8] Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells
    Carter, BZ
    Mak, DH
    Schober, WD
    Cabreira-Hansen, M
    Beran, M
    McQueen, T
    Chen, WJ
    Andreeff, M
    BLOOD, 2006, 107 (04) : 1555 - 1563
  • [9] Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells
    Lan, Xiaoying
    Hu, Min
    Jiang, Liling
    Wang, Jiamin
    Meng, Yi
    Chen, Xinmei
    Liu, Aochu
    Ding, Wa
    Zhang, Haichuan
    Zhou, Huan
    Liu, Bingyuan
    Peng, Guanjie
    Liao, Siyan
    Chen, Xin
    Liu, Jinbao
    Shi, Xianping
    JOURNAL OF ETHNOPHARMACOLOGY, 2023, 301
  • [10] Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells
    Shima, Takafumi
    Taniguchi, Kohei
    Tokumaru, Yoshihisa
    Inomata, Yosuke
    Arima, Jun
    Lee, Sang-Woong
    Takabe, Kazuaki
    Yoshida, Kazuhiro
    Uchiyama, Kazuhisa
    ONCOLOGY REPORTS, 2022, 47 (01)
1234